Chengdu Suncadia Medicine Co., Ltd.

This trial tests an experimental drug called HRS-5965 in people with primary IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug can reduce protein leakage in the urine, a sign of kidney damage. About 123 adults with confirmed IgA nep…

This phase 3 trial tested a new drug called HRS-5965 in 39 adults with paroxysmal nocturnal hemoglobinuria (PNH) who remained anemic even after standard anti-C5 antibody treatment. The study aimed to see if the drug could raise hemoglobin levels without needing blood transfusions…

This Phase 3 study tested a new oral medication, HRS-5965, against the standard infusion eculizumab in 76 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. The main goal was to see if HRS-5965 could raise hemoglobin levels to normal without needing blo…

This early-stage study tests a new oral drug called HRS-3095 in 66 healthy adults aged 18-55. The main goal is to check safety and how the body processes the drug, not to treat any disease. Results will help design future studies for chronic spontaneous urticaria (long-term hives…

This completed Phase 1 study looked at how the drug HRS-5965 behaves in people with mild or moderate liver impairment compared to those with normal liver function. Twenty-four adults took a single 50 mg dose of the drug. The goal was to measure drug levels in the blood and check …

This completed Phase 1 trial tested 16 healthy adults to compare how well HRS-5965 is absorbed when taken as a capsule versus a tablet. The goal was to measure relative bioavailability on an empty stomach. This is a preliminary step before testing the drug in patients with blood …